Home > News > Interview with Karen J. Brunke, Ph. D. at Targesome, Inc.
January 20th, 2003
Interview with Karen J. Brunke, Ph. D. at Targesome, Inc.
Abstract:
Targesome Inc., co-founded by Drs. King Li and Mark Bednarski in late 1999, is developing nanoparticles that can be used for drug delivery. Any drug can be attached to the surface of the nanoparticle, resulting in improved therapeutic properties such as efficacy, safety, and increased half-life in the blood for small molecule drugs (thereby allowing less frequent intravenous dosing).
Source:
NanoApex
Bookmark:
| Related News Press |
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||